Search

Displaying results 1141 - 1150 of 10000 in total
  1. Drug

    Talimogene laherparepvec

    go.drugbank.com/drugs/DB13896
    ApprovedInvestigational

    It was approved by the FDA in 2015 under the market name Imlygic. In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221]. … Alternatively, although talimogene laherparepvec also enters healthy cells, it is not designed to multiply inside them [L2221].

  2. Drug

    Bexagliflozin

    go.drugbank.com/drugs/DB12236
    ApprovedInvestigational

    Its use is not recommended in patients with type 1 diabetes since it may increase their risk of diabetic ketoacidosis.[L44758] … [A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes.

  3. Drug

    Zenocutuzumab

    go.drugbank.com/drugs/DB15559
    ApprovedInvestigational

    [L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma. … [A264833] On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab for the treatment of non-small cell lung cancer and pancreatic adenocarcinoma.

  4. Drug

    Potassium bicarbonate

    go.drugbank.com/drugs/DB11098
    ApprovedInvestigational

    It is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. It is used in medicine as an antacid. … [T141] It is registered in the FDA under the section of suitable, safe and effective ingredients for OTC antacids.[L1836] This FDA denomination classifies potassium bicarbonate as a GRAS ingredient.

    Mixtures: Multi-min Electro C Pow Plus B2
  5. Drug

    Nimodipine

    go.drugbank.com/drugs/DB00393
    ApprovedInvestigational

    It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. … By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction.

  6. Drug

    Artemether

    go.drugbank.com/drugs/DB06697
    ApprovedInvestigational

    </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.

  7. Drug

    Fingolimod

    go.drugbank.com/drugs/DB08868
    ApprovedInvestigational

    It was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.

  8. Drug

    Olanzapine

    go.drugbank.com/drugs/DB00334
    ApprovedInvestigational

    [A177011] Olanzapine was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.[T548]

    Products: Nu-olanzapine, Nb-olanzapine
  9. Drug

    Etoperidone

    go.drugbank.com/drugs/DB09194
    ApprovedWithdrawn

    [T45] Etoperidone was developed by Angelini Francesco ACRAF.[A4909]

  10. Drug

    Dibotermin alfa

    go.drugbank.com/drugs/DB11639
    ApprovedInvestigational

    Dibotermin alfa was approved by the EMA in 2002 as Inductos for implantation matrix. In 2004, it was approved by the FDA and is marketed as Infuse.